COMP <GO>
CELZ vs BTTC // EV/EBITDA & P/E VALUATION
Creative Medical Technology Holdings Inc. (NASDAQ) VS. Black Titan Corporation (NASDAQ) • 15-METRIC TALLY: CELZ 1
— BTTC 2
■ METRIC PARITY
LAST: $0.68 (-5.78%) • MKT CAP: $5.2M
valuation
—
LAST: $0.35 (+4.23%) • MKT CAP: $5.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CELZ VS. BTTC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CELZ | BTTC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 63.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -2.73% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -45.50% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 1/9 | +2.00 | CELZ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.7 | 36.3 | -4.57 | BTTC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.2M | $5.3M | -$101.1K | BTTC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CELZ REV | BTTC REV | CELZ GROSS % | BTTC GROSS % | CELZ FCF | BTTC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.0K | $0 | 63.4% | — | -$5.9M | -$143.2K |
| FY 2024 | $11.0K | — | 60.0% | — | -$5.3M | — |
| FY 2023 | $9.0K | — | — | — | -$8.0M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CELZ // BETA —
BTTC // BETA —